menu
    • menu

    Company profile for Sparian Biosciences

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Central nervous system diseases represent a primary unmet need, but there has been little innovation and development recently. Sparian was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD PhD to develop therapeutics targeting the brain through innovative science and novel drug discovery...
    Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Central nervous system diseases represent a primary unmet need, but there has been little innovation and development recently. Sparian was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD PhD to develop therapeutics targeting the brain through innovative science and novel drug discovery.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sparian BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    180 Varick Street, New York, New York 10014-0121
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sparianbiosciences.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sparian-biosciences/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sparian Biosciences Wins $19.5M NIH/NIDA Grant for SBS-226
    Sparian Biosciences Wins $19.5M NIH/NIDA Grant for SBS-226

    14 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/14/2981367/0/en/Sparian-Biosciences-Awarded-19-5-Million-Five-Year-NIH-NIDA-Grant-to-Fund-Development-of-SBS-226-for-Opiate-Use-Disorder-Opiate-Withdrawal-Syndrome-Through-Phase-1-Clinical-Develop.html

    GLOBENEWSWIRE
    14 Nov 2024
    Share Share
    Sparian Biosciences Forms Science Advisory Board
    Sparian Biosciences Forms Science Advisory Board

    13 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/13/2980573/0/en/Sparian-Biosciences-Announces-Formation-of-its-Science-Advisory-Board.html

    GLOBENEWSWIRE
    13 Nov 2024
    Share Share
    Sparian Bio Reports Phase 1 Trial Results of SBS-1000 Analgesic
    Sparian Bio Reports Phase 1 Trial Results of SBS-1000 Analgesic

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2979419/0/en/Sparian-Biosciences-Announces-Results-from-the-Phase-1-Clinical-Trial-of-First-in-Class-Novel-Arylepoxamide-Receptor-AEAr-Agonist-Analgesic-SBS-1000.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share
    Sparian Awarded $19M Five-Year NIH/ NIDA Grant to Fund Development of SBS-518
    Sparian Awarded $19M Five-Year NIH/ NIDA Grant to Fund Development of SBS-518

    08 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/08/2720562/0/en/Sparian-Biosciences-Awarded-19-Million-Five-Year-NIH-NIDA-Grant-to-Fund-Development-of-SBS-518-for-Stimulant-Use-Disorder-Through-Phase-1-Clinical-Development.html

    GLOBENEWSWIRE
    08 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search